DE60103453D1 - Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel - Google Patents

Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel

Info

Publication number
DE60103453D1
DE60103453D1 DE60103453T DE60103453T DE60103453D1 DE 60103453 D1 DE60103453 D1 DE 60103453D1 DE 60103453 T DE60103453 T DE 60103453T DE 60103453 T DE60103453 T DE 60103453T DE 60103453 D1 DE60103453 D1 DE 60103453D1
Authority
DE
Germany
Prior art keywords
medicament
albumin
treatment
solid tumors
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60103453T
Other languages
English (en)
Other versions
DE60103453T2 (de
Inventor
Marco Falciani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
ACS Dobfar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11445079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60103453(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ACS Dobfar SpA filed Critical ACS Dobfar SpA
Application granted granted Critical
Publication of DE60103453D1 publication Critical patent/DE60103453D1/de
Publication of DE60103453T2 publication Critical patent/DE60103453T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60103453T 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel Expired - Lifetime DE60103453T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI001107 2000-05-18
IT2000MI001107A ITMI20001107A1 (it) 2000-05-18 2000-05-18 Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel

Publications (2)

Publication Number Publication Date
DE60103453D1 true DE60103453D1 (de) 2004-07-01
DE60103453T2 DE60103453T2 (de) 2005-06-23

Family

ID=11445079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60103453T Expired - Lifetime DE60103453T2 (de) 2000-05-18 2001-04-27 Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel

Country Status (23)

Country Link
US (1) US6652884B2 (de)
EP (1) EP1155692B1 (de)
JP (1) JP2001354559A (de)
KR (2) KR20010105248A (de)
CN (1) CN1198609C (de)
AT (1) ATE267594T1 (de)
AU (1) AU781517B2 (de)
BR (1) BR0102040A (de)
CA (1) CA2345482A1 (de)
DE (1) DE60103453T2 (de)
DK (1) DK1155692T3 (de)
ES (1) ES2221874T3 (de)
HK (1) HK1040368A1 (de)
HU (1) HU229909B1 (de)
IL (1) IL142674A0 (de)
IT (1) ITMI20001107A1 (de)
MX (1) MXPA01004980A (de)
NO (1) NO330511B1 (de)
NZ (1) NZ511201A (de)
PT (1) PT1155692E (de)
RU (1) RU2270003C2 (de)
TR (1) TR200101353A3 (de)
ZA (1) ZA200103755B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CN1925874B (zh) * 2002-12-09 2014-12-17 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
MX339142B (es) * 2005-02-18 2016-05-13 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
KR101457834B1 (ko) 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
JP2009512682A (ja) * 2005-10-21 2009-03-26 パナセア バイオテック リミテッド 少なくとも１種の抗癌性薬物および少なくとも１種のポリマーを含む医薬組成物
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP3470071A1 (de) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Brustkrebstherapie auf basis des hormonrezeptorstatus mit nanopartikel mit taxan
KR20150002886A (ko) 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
PL2155188T3 (pl) 2007-06-01 2014-03-31 Abraxis Bioscience Llc Sposoby i kompozycje do leczenia nawrotowego raka
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR101090505B1 (ko) * 2008-12-30 2011-12-06 최은아 난담반을 포함하는 암 예방 및 치료용 조성물
MY175260A (en) 2009-04-15 2020-06-17 Abraxis Bioscience Llc Prion free nanoparticle compositions and methods of making thereof
MX359413B (es) 2010-03-26 2018-09-27 Abraxis Bioscience Llc Metodos de tratamiento de carcinoma hepatocelular.
CA3087813A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
NZ703047A (en) 2010-03-29 2016-11-25 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ604031A (en) 2010-06-04 2015-05-29 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CN109288789A (zh) 2011-04-28 2019-02-01 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
WO2013090634A1 (en) 2011-12-14 2013-06-20 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
MX370662B (es) 2013-03-12 2019-12-19 Abraxis Bioscience Llc Composiciones que comprenden nanopartículas de paclitaxel y albúmina para usarse en el tratamiento de cáncer.
EP2968253A4 (de) * 2013-03-13 2016-11-02 Abraxis Bioscience Llc Verfahren zur behandlung von pädiatrischen soliden tumoren
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
PL3313401T3 (pl) 2015-06-29 2022-02-07 Abraxis Bioscience, Llc Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych
CN109906088A (zh) * 2016-08-26 2019-06-18 奥野哲治 微血管血流减少剂及其应用
TWI660728B (zh) 2018-02-09 2019-06-01 國立交通大學 胺基喹唑啉衍生物及其醫藥組合物與用途
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433723T3 (de) 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
KR100789008B1 (ko) * 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
EP1100494A1 (de) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmazeutische zubereitung enthaltend eine wässrige lösung aus paclitaxel und albumin

Also Published As

Publication number Publication date
ITMI20001107A1 (it) 2001-11-18
DE60103453T2 (de) 2005-06-23
IL142674A0 (en) 2002-03-10
US6652884B2 (en) 2003-11-25
US20010046961A1 (en) 2001-11-29
KR20080091747A (ko) 2008-10-14
TR200101353A2 (tr) 2001-12-21
TR200101353A3 (tr) 2001-12-21
CN1198609C (zh) 2005-04-27
AU3876501A (en) 2001-11-22
ATE267594T1 (de) 2004-06-15
JP2001354559A (ja) 2001-12-25
ZA200103755B (en) 2001-11-15
HUP0102039A2 (hu) 2002-05-29
NZ511201A (en) 2002-11-26
PT1155692E (pt) 2004-09-30
NO20012409D0 (no) 2001-05-16
BR0102040A (pt) 2002-03-19
AU781517B2 (en) 2005-05-26
MXPA01004980A (es) 2002-08-06
NO330511B1 (no) 2011-05-09
RU2270003C2 (ru) 2006-02-20
HK1040368A1 (en) 2002-06-07
CA2345482A1 (en) 2001-11-18
CN1324613A (zh) 2001-12-05
DK1155692T3 (da) 2004-08-09
HU0102039D0 (en) 2001-07-30
ITMI20001107A0 (it) 2000-05-18
HUP0102039A3 (en) 2002-12-28
NO20012409L (no) 2001-11-19
KR20010105248A (ko) 2001-11-28
EP1155692A1 (de) 2001-11-21
EP1155692B1 (de) 2004-05-26
HU229909B1 (en) 2014-12-29
ES2221874T3 (es) 2005-01-16

Similar Documents

Publication Publication Date Title
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
CY1124464T1 (el) Ενωση 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτης για μη-νοηματικη καταστολη και τη θεραπεια ασθενειας
CY1112946T1 (el) 4-υδροξυβενζομορφανια
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
HK1148689A1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
DE59006880D1 (de) Gerät zur Herstellung von Formkörpern und Verwendung desselben zur Herstellung von Inlays, Onlays, und Kronen in der Zahnmedizin.
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DE69921178D1 (de) Hapten-träger-konjugate zur behandlung und vorbeugung von nikotinabhängigkeit
ATE318590T1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
ATE316786T1 (de) Behandlung von mukositis
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
DE60003182D1 (de) Extendin-4 konjugate und ihre medizinische verwendung
DE60202677D1 (de) Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
RU2001113688A (ru) Применение паклитаксела, стабилизированного альбумином, для изготовления лекарственного средства для лечения солидных опухолей и лекарственное средство, полученное указанным способом
EA200500399A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
DE69815094D1 (de) 2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
DE60203197D1 (de) 4-(oxadiazol-3-yl)-1,4-diazabizyklo[3.2.2]-nonanderivate, ihre herstellung und therapeutische verwendung
DE60015560D1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
DE69604071T2 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
DE69326627T2 (de) Therapeutisches Mittel gegen drohenden Abortus
ATE272641T1 (de) Neue xanthon derivate, deren herstellung und verwendung als arzneimittel
ATE404519T1 (de) Hyperforinderivate, ihre verwendung sowie diese enthaltende zubereitungen
DE3788888T2 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
ATE80800T1 (de) Verwendung von suramin und physiologisch vertraeglichen derivaten davon, gegebenenfalls in kombination mit anti-androgenen mitteln zur herstellung von arzneimitteln zur behandlung des humanen prostatakarzinoms.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ABRAXIS BIOSCIENCE, INC. (N.D.GES.D. STAATES D, US

8327 Change in the person/name/address of the patent owner

Owner name: ABRAXIS BIOSCIENCE,LLC (N. D. GES. D.STAATES D, US